Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Diagnosis and evaluation of von Willebrand disease (VWD) is a critical step in ensuring that patients receive appropriate treatment and avoid unnecessary complications. This page is designed for international patients and healthcare professionals seeking a clear, detailed overview of how VWD is identified, assessed, and classified at Liv Hospital. According to the World Federation of Hemophilia, VWD is the most common inherited bleeding disorder, affecting up to 1% of the global population. Early and accurate diagnosis can dramatically improve quality of life, especially for those traveling for specialized care. In the sections below, you will learn about the clinical presentation, the suite of laboratory tests, advanced imaging options, and how our multidisciplinary team interprets results to create a personalized management plan.
Von Willebrand disease is a heterogeneous group of bleeding disorders caused by quantitative or qualitative defects in von Willebrand factor (VWF), a protein essential for platelet adhesion and clot stabilization. The disease is classified into three major types:
Clinical manifestations vary according to type and severity. Common symptoms include mucocutaneous bleeding (nosebleeds, gum bleeding), menorrhagia, easy bruising, and prolonged bleeding after dental procedures or surgery. In severe cases, especially Type 3, patients may experience joint and muscle hemorrhages similar to hemophilia. Recognizing these patterns during the initial assessment guides the subsequent diagnostic work‑up.
At Liv Hospital, clinicians use a structured questionnaire to capture these details, ensuring a comprehensive baseline for diagnosis and evaluation.
The first step in the diagnostic pathway is a thorough clinical assessment. This involves collecting detailed personal and familial bleeding histories, reviewing medication use (especially anticoagulants or antiplatelet agents), and documenting any prior surgical outcomes. The assessment also evaluates comorbid conditions that may influence bleeding risk, such as liver disease or thyroid dysfunction.
Our international patient coordinators assist visitors in preparing their medical records before arrival, allowing physicians to review prior laboratory results and imaging studies. This pre‑visit preparation shortens the time needed for in‑clinic evaluation and ensures that all relevant data are available for accurate interpretation.
These elements form the foundation for targeted laboratory investigations, aligning with the overall goal of precise diagnosis and evaluation.
Laboratory testing is the cornerstone of confirming VWD and determining its subtype. The most frequently ordered assays include:
All tests are performed in our JCI‑accredited hematology laboratory, which follows strict quality‑control protocols. Blood samples are drawn under standardized conditions to minimize pre‑analytical variability, a crucial factor for accurate VWF measurement.
These results, combined with clinical data, enable a comprehensive diagnosis and evaluation that guides therapeutic decisions.
refine the assessment, especially in complex cases or when planning surgical interventions. At Liv Hospital, we employ the following modalities:
These tools are integrated into a multidisciplinary review, where hematologists, genetic counselors, and radiologists discuss findings to reach a consensus on disease classification and severity.
Genetic analysis is recommended in the following scenarios:
Results are communicated in a culturally sensitive manner, with interpreter support available for all international patients, ensuring that the diagnosis and evaluation process remains clear and patient‑centered.
Accurate interpretation requires distinguishing VWD from other bleeding disorders such as platelet function defects, hemophilia A, or acquired von Willebrand syndrome (often secondary to cardiovascular disease or autoimmune conditions). The differential diagnosis follows a systematic algorithm:
Severity grading is based on both laboratory values and clinical bleeding scores. The International Society on Thrombosis and Haemostasis (ISTH) recommends categorizing VWD as mild, moderate, or severe, guiding treatment intensity.
By integrating laboratory data with clinical presentation, our team provides a nuanced diagnosis and evaluation that informs individualized therapy plans.
Once the diagnosis and severity are established, treatment is tailored to the patient’s lifestyle, bleeding risk, and personal preferences. Options include:
Our international patient services team coordinates pre‑operative planning, including timing of factor replacement and postoperative monitoring, ensuring seamless care for patients traveling from abroad. Follow‑up schedules are customized, with telemedicine options available for ongoing assessment.
Regular monitoring includes repeat VWF assays after major interventions, periodic bleeding score reassessment, and evaluation of inhibitor development. Patients are educated on self‑infusion techniques when appropriate, and a 24‑hour hotline provides immediate assistance for breakthrough bleeding.
Liv Hospital combines JCI‑accredited clinical excellence with a dedicated international patient program. Our hematology department features board‑certified specialists, state‑of‑the‑art laboratory facilities, and a multidisciplinary team that includes genetic counselors, physiotherapists, and nutritionists. From the moment you arrive in Istanbul, we handle appointments, airport transfers, interpreter services, and comfortable accommodation options, allowing you to focus on your health. Trust our experience to deliver precise diagnosis and evaluation and a personalized treatment pathway that meets global standards.
Ready to take the next step in your care journey? Contact Liv Hospital today to schedule a comprehensive evaluation for von Willebrand disease and benefit from our world‑class expertise and seamless international patient support.
Send us all your questions or requests, and our expert team will assist you.
Von Willebrand disease comprises three primary categories. Type 1 accounts for about 70‑80 % of cases and involves a reduced amount of functional VWF. Type 2 includes qualitative abnormalities that affect VWF function; it is further divided into subtypes 2A, 2B, 2M, and 2N, each with distinct laboratory patterns. Type 3 is the rarest and most severe form, characterized by almost no detectable VWF, leading to severe bleeding similar to hemophilia. Recognizing the type guides both laboratory work‑up and therapeutic choices.
The diagnostic pathway starts with a structured clinical assessment, including the Bleeding Assessment Tool, family pedigree, medication review, and physical examination. Laboratory evaluation follows, typically measuring VWF antigen (VWF:Ag), ristocetin cofactor activity (VWF:RCo), factor VIII activity (FVIII:C), VWF multimer analysis, and VWF collagen binding (VWF:CB). Results are interpreted against established ratios to determine the VWD type, and genetic testing may be added for ambiguous cases or severe phenotypes.
VWF antigen quantifies the protein amount, while ristocetin cofactor activity assesses its functional ability to bind platelets. Factor VIII coagulant activity evaluates the stabilizing effect of VWF on FVIII. Multimer analysis separates VWF molecules by size to detect qualitative defects, especially useful for Type 2 subtyping. VWF collagen binding identifies specific functional defects, such as those seen in Type 2M. Together, these assays provide a comprehensive picture of VWF status.
Genetic sequencing of the VWF gene is useful when laboratory results are incongruent with clinical severity, when a patient has a strong family history but normal assay values, or when precise subtype identification influences prophylactic strategies for major surgery. It also assists relatives who seek carrier status confirmation. Liv Hospital offers targeted next‑generation sequencing with counseling in multiple languages.
Desmopressin (DDAVP) is first‑line for many Type 1 and some Type 2 patients, raising endogenous VWF levels temporarily. For Type 3 or DDAVP‑non‑responders, VWF‑containing factor concentrates are administered, especially around surgery. Antifibrinolytic agents such as tranexamic acid control mucosal bleeding. In select severe cases, Liv Hospital can enroll patients in international gene‑therapy studies aiming to provide long‑term correction of the VWF defect.
The International Patient Program assists travelers by arranging airport transfers, accommodation, and multilingual interpreters. Prior to arrival, coordinators collect medical records and previous test results to streamline in‑clinic evaluation. After diagnosis, a personalized care plan is created, and patients receive 24‑hour hotline access, tele‑medicine appointments, and education on self‑infusion techniques when appropriate.
BlogHematologyOct 06, 2025Rare bleeding disorders affect millions worldwide, leaving patients and healthcare providers searching for ...
BlogHematologyFeb 19, 2026Many people wonder if vitamin B12 can thin your blood. This is a big concern because we need to know how su...
BlogHematologyOct 21, 2025Inherited bleeding disorders affect thousands worldwide. Hemophilia and von Willebrand disease are the most...
BlogHematologyFeb 19, 2026Blood donation is a key act that saves many lives. But, some medical conditions, like hemophilia, make it r...
BlogHematologyFeb 19, 2026We are looking into how desmopressin changes medicine. It’s a synthetic hormone that has made a big d...
BlogHematologyFeb 19, 2026Diagnosing some blood disorders is tough. Conditions like Von Willebrand disease and myelodysplastic syndro...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 510 71 24
